MergerJul 10, 2026, 04:07 PM
InMed Pharmaceuticals Amends Merger Agreement with Mentari
AI Summary
InMed Pharmaceuticals Inc. and Mentari Therapeutics, Inc. entered into Amendment No. 1 to their Agreement and Plan of Merger and Reorganization, originally dated May 19, 2026. The amendment clarifies the sequencing of the contemplated transactions, including InMed's name change to Mentari Therapeutics, Inc. and redomestication to Nevada, and introduces a mechanism for potential additional private placement financing for Mentari. Additionally, the amendment clarifies the intended tax treatment of the merger. A joint press release announced the amendment and the filing of a Form S-4 registration statement on July 2, 2026, with the merger still expected to close in Q4 2026.
Key Highlights
- InMed Pharmaceuticals and Mentari Therapeutics amended their Agreement and Plan of Merger and Reorganization.
- The amendment clarifies the sequencing of transactions, including InMed's name change to Mentari Therapeutics, Inc. and redomestication to Nevada.
- It introduces a 'Company PIPE Amendment' to facilitate potential additional private placement financing for Mentari pre-closing.
- The amendment clarifies the intended tax treatment of the Merger, confirming it as a reorganization under Section 368(a).
- The Company Equity Value is set at $125,000,000.
- InMed also filed a registration statement on Form S-4 on July 2, 2026, for the proposed merger.
- The merger is expected to close in the fourth quarter of 2026, subject to shareholder approvals and S-4 effectiveness.
Price Impact
More from INM